Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08FAB
|
||||
| Former ID |
DNC005714
|
||||
| Drug Name |
3-(naphthalen-2-yl)pyridine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [529667] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H11N
|
||||
| Canonical SMILES |
C1=CC=C2C=C(C=CC2=C1)C3=CN=CC=C3
|
||||
| InChI |
1S/C15H11N/c1-2-5-13-10-14(8-7-12(13)4-1)15-6-3-9-16-11-15/h1-11H
|
||||
| InChIKey |
JVWGLICJXUMGHN-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cytochrome P450 19 | Target Info | Inhibitor | [529834] | |
| Cytochrome P450 11B1, mitochondrial | Target Info | Inhibitor | [529667] | ||
| NetPath Pathway | FSH Signaling Pathway | ||||
| PANTHER Pathway | Androgen/estrogene/progesterone biosynthesis | ||||
| PathWhiz Pathway | Androgen and Estrogen MetabolismPW000141:Steroidogenesis | ||||
| WikiPathways | Metapathway biotransformation | ||||
| Tryptophan metabolism | |||||
| Oxidation by Cytochrome P450 | |||||
| Ovarian Infertility Genes | |||||
| Metabolism of steroid hormones and vitamin D | |||||
| FSH signaling pathway | |||||
| Integrated Breast Cancer Pathway | |||||
| Phase 1 - Functionalization of compoundsWP702:Metapathway biotransformation | |||||
| Corticotropin-releasing hormone | |||||
| References | |||||
| Ref 529667 | J Med Chem. 2008 Oct 9;51(19):6138-49. Epub 2008 Sep 3.Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. | ||||
| Ref 529834 | J Med Chem. 2008 Dec 25;51(24):8077-87.In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.